SK285344B6 - Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb - Google Patents

Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb Download PDF

Info

Publication number
SK285344B6
SK285344B6 SK79-99A SK7999A SK285344B6 SK 285344 B6 SK285344 B6 SK 285344B6 SK 7999 A SK7999 A SK 7999A SK 285344 B6 SK285344 B6 SK 285344B6
Authority
SK
Slovakia
Prior art keywords
cells
pharmaceutical compositions
mcf
treatment
preparation
Prior art date
Application number
SK79-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK7999A3 (en
Inventor
Jean-Claude Breliere
Pascual Ferrara
Christine Lebouteiller
Raymond Paul
Jorge Rosenfeld
Broeck Didier Van
Original Assignee
Sanofi - Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi - Aventis filed Critical Sanofi - Aventis
Publication of SK7999A3 publication Critical patent/SK7999A3/sk
Publication of SK285344B6 publication Critical patent/SK285344B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
SK79-99A 1996-07-29 1997-07-28 Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb SK285344B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609531A FR2751645B1 (fr) 1996-07-29 1996-07-29 Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
PCT/FR1997/001409 WO1998004251A1 (fr) 1996-07-29 1997-07-28 Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales

Publications (2)

Publication Number Publication Date
SK7999A3 SK7999A3 (en) 2000-01-18
SK285344B6 true SK285344B6 (sk) 2006-11-03

Family

ID=9494593

Family Applications (1)

Application Number Title Priority Date Filing Date
SK79-99A SK285344B6 (sk) 1996-07-29 1997-07-28 Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb

Country Status (31)

Country Link
US (1) US6235791B1 (no)
EP (1) EP0917464B1 (no)
JP (1) JP3538431B2 (no)
KR (1) KR100315559B1 (no)
CN (1) CN1154483C (no)
AR (1) AR008090A1 (no)
AT (1) ATE266392T1 (no)
AU (1) AU735948B2 (no)
BR (1) BR9711606A (no)
CA (1) CA2261827C (no)
CZ (1) CZ294266B6 (no)
DE (1) DE69729099T2 (no)
DK (1) DK0917464T3 (no)
EE (1) EE03851B1 (no)
ES (1) ES2221061T3 (no)
FR (1) FR2751645B1 (no)
HU (1) HU224346B1 (no)
ID (1) ID17707A (no)
IL (1) IL127922A (no)
IS (1) IS2049B (no)
MY (1) MY120426A (no)
NO (1) NO322897B1 (no)
NZ (1) NZ333957A (no)
PT (1) PT917464E (no)
RU (1) RU2176502C2 (no)
SI (1) SI0917464T1 (no)
SK (1) SK285344B6 (no)
TR (1) TR199900161T2 (no)
UA (1) UA61080C2 (no)
WO (1) WO1998004251A1 (no)
ZA (1) ZA976697B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2143403B1 (es) * 1998-03-13 2001-01-01 Consejo Superior Investigacion Derivados de ciclopropenilaminas como agentes anticancerosos.
GB9814036D0 (en) 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2795724B1 (fr) * 1999-07-02 2002-12-13 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
DE50207026D1 (de) * 2001-08-23 2006-07-06 Bayer Cropscience Sa Substituierte propargylamine
FR2887454B1 (fr) * 2005-06-28 2009-06-05 Sanofi Aventis Sa Combinaisons antitumorales contenant des derives du taxane et des sigma ligands
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
TW200808773A (en) 2006-06-23 2008-02-16 Abbott Lab Cyclopropyl amine derivatives
EP2126574B1 (en) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AU2013299330B2 (en) * 2012-08-01 2018-01-25 Merck Sharp & Dohme Llc Alpha7 nicotinic acetylcholine receptor modulators and uses thereof-i
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
HRP20211960T1 (hr) 2016-03-22 2022-03-18 Merck Sharp & Dohme Corp. Alosterični modulatori nikotinskih acetilcolinskih receptora
KR20230069132A (ko) 2020-09-17 2023-05-18 멜레티오스 테라퓨틱스 바이러스 감염을 치료하기 위한 화합물 및 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674832A (en) 1968-08-22 1972-07-04 Schering Corp Cyclopropane carboxylic acid derivatives
FR2132547A1 (en) 1971-04-08 1972-11-24 Clin Byla Ets Substd phenyl alkyl or alkenyl amides - useful as analgesics and antiinflammatories
GB1475314A (en) * 1973-11-02 1977-06-01 Cm Ind Phenyl-propylamine derivatives
US4104383A (en) 1973-11-02 1978-08-01 C M Industries Derivatives of phenylpropenylamine
IT1113391B (it) 1979-05-09 1986-01-20 Maggioni Farma Derivati fenilcicloesanici ad attivita' antidepressiva
US4537902A (en) 1979-06-11 1985-08-27 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
FR2641276B1 (fr) 1988-12-30 1991-07-12 Sanofi Sa Derives du benzene, leur preparation et les compositions pharmaceutiques en contenant
JP2814694B2 (ja) 1989-07-21 1998-10-27 セイコーエプソン株式会社 識別コード読み書き構造及びその装置及びその方法
FR2663328B1 (fr) * 1990-06-14 1994-08-05 Sanofi Sa Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2694287B1 (fr) * 1992-07-31 1994-09-16 Jouveinal Inst Rech Nouvelles cycloalkylalkylamines ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique.
US5849760A (en) * 1993-12-09 1998-12-15 Institut De Recherche Jouveinal 2-(arylalkenyl)azacycloalkane derivatives as ligands for sigma receptors
FR2724656B1 (fr) * 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2725445B1 (fr) * 1994-10-10 1996-10-31 Adir Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Also Published As

Publication number Publication date
IL127922A0 (en) 1999-11-30
RU2176502C2 (ru) 2001-12-10
ID17707A (id) 1998-01-22
FR2751645A1 (fr) 1998-01-30
HUP9902806A3 (en) 2000-12-28
KR100315559B1 (ko) 2001-12-12
DK0917464T3 (da) 2004-08-16
JP2000500782A (ja) 2000-01-25
ES2221061T3 (es) 2004-12-16
BR9711606A (pt) 1999-08-24
CN1226825A (zh) 1999-08-25
NO322897B1 (no) 2006-12-07
EE9900029A (et) 1999-08-16
DE69729099D1 (de) 2004-06-17
NO990401L (no) 1999-03-25
CA2261827A1 (fr) 1998-02-05
SK7999A3 (en) 2000-01-18
EE03851B1 (et) 2002-10-15
PT917464E (pt) 2004-08-31
MY120426A (en) 2005-10-31
EP0917464A1 (fr) 1999-05-26
AU735948B2 (en) 2001-07-19
CN1154483C (zh) 2004-06-23
WO1998004251A1 (fr) 1998-02-05
AU3855197A (en) 1998-02-20
ZA976697B (en) 1998-02-10
CZ294266B6 (cs) 2004-11-10
CA2261827C (fr) 2004-10-26
UA61080C2 (uk) 2003-11-17
US6235791B1 (en) 2001-05-22
IS2049B (is) 2005-09-15
NO990401D0 (no) 1999-01-28
IS4946A (is) 1999-01-19
SI0917464T1 (en) 2004-12-31
JP3538431B2 (ja) 2004-06-14
IL127922A (en) 2003-11-23
KR20000029629A (ko) 2000-05-25
AR008090A1 (es) 1999-12-09
ATE266392T1 (de) 2004-05-15
TR199900161T2 (xx) 1999-04-21
NZ333957A (en) 2000-09-29
CZ24299A3 (cs) 1999-05-12
HU224346B1 (hu) 2005-08-29
FR2751645B1 (fr) 1998-12-24
HU9902806A (en) 2000-04-28
EP0917464B1 (fr) 2004-05-12
DE69729099T2 (de) 2005-05-12

Similar Documents

Publication Publication Date Title
SK285344B6 (sk) Použitie cis-N-cyklohexyl-N-etyl-[3-(3-chlór-4- cyklohexylfenyl)alyl]amínu na prípravu farmacetických kompozícií na liečbu proliferatívnych chorôb
EP0616812B1 (en) Combination with anti-hormonal compounds and binding molecules for the treatment of cancer
Rérole et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy
JPH05286859A (ja) チロシンプロテインキナーゼインヒビター含有癌治療剤
JP6810146B2 (ja) 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート
US20040019060A1 (en) Sigma receptor ligands and their medical uses
US20100305129A1 (en) Compositions and methods for inhibiting growth and metastasis of melanoma
EP1653943B3 (en) Catechol derivatives for the treatment of cancer
WO2003073999A2 (en) Pini-modulating compounds and methods of use thereof
Arnst et al. Colchicine binding site agent DJ95 overcomes drug resistance and exhibits antitumor efficacy
TW200804350A (en) Aryl-substituted quinazolones, and uses thereof
US20240066032A1 (en) Methods of treating prostate cancer
US20090041767A1 (en) Pharmaceutical combinations
US20170071905A1 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
Gardette et al. Evaluation of two 125 I-radiolabeled acridine derivatives for Auger-electron radionuclide therapy of melanoma
Tallett et al. Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells
McLAUGHLIN et al. Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor.
Pirker et al. Enhancement of the activity of immunotoxins by analogues of verapamil
IL95875A (en) Pharmaceutical compositions containing analogues of illudin m and s for inhibiting tumor cell growth
WO2005034856A2 (en) Targeted drug-formaldehyde conjugates and methods of making and using the same
US7781398B2 (en) Drug comprising synthetic peptide analogs for the treatment of cancer
CN101083990A (zh) 破坏brca2－rad51相互作用的组合物和方法
US7259278B2 (en) Anti-S-phase tubulin ligands
US20230321062A1 (en) Combination therapies
WO2004002429A2 (en) Methods of inhibiting pin1-associated states using a fredericamycin a compound

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20090728